Construction of 124I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients.

Xiaoyi GuoNina ZhouZuhua ChenTeli LiuXiaoxia XuXia LeiLin ShenJing GaoZhi YangHua Zhu

Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2020)

The findings described here demonstrated that 124I-trastuzumab was feasible to detect HER2-positive lesions in primary and metastatic gastric cancer patients and to differentiate HER2-positive and HER2-negative lesions quantitatively.

Keyphrases

pet imaging
end stage renal disease
ejection fraction
epidermal growth factor receptor
newly diagnosed
chronic kidney disease
squamous cell carcinoma
poor prognosis
peritoneal dialysis
patient reported outcomes
positron emission tomography
binding protein
long non coding rna
patient reported